Spectrumcare Rehabilitation Medical Center

Spectrumcare Rehabilitation Medical Center was paid $1.87M by Medicaid between Jan 2018 and Nov 2024, across 27 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 36% of everything it billed.

Compared with peers

Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in California

Rank by total paid#9 of 70

Median peer was paid$39K

This provider vs. median48×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	6,065	$140K
2019	6,291	$229K
2020	4,765	$218K
2021	8,414	$434K
2022	7,143	$407K
2023	2,994	$191K
2024incomplete	3,164	$248K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	36%	2,664	2,480	$669K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	22%	17,899	15,859	$413K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	16%	3,772	2,518	$291K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	12%	3,005	2,793	$231K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.6%	3,660	2,411	$85K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.7%	258	234	$51K
J3490	Unclassified drugs	1.8%	740	682	$34K
76942		1.3%	1,672	1,611	$24K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	1.2%	1,286	1,237	$22K
62370		<1%	1,228	1,195	$13K
76881		<1%	227	222	$7K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	110	110	$6K

15 more codes

62369		<1%	353	$6K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	533	$5K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	17	$3K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	68	$2K
62368		<1%	179	$2K
95970		<1%	100	$2K
62367		<1%	183	$989.85
96103		<1%	53	$308.73
96130		<1%	12	$273.51
96127		<1%	30	$189.37
99152		<1%	55	$189.25
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	12	$58.67
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	659	$25.88
G0444	Annual depression screening, 5 to 15 minutes	0%	45	$0.00
99408		0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGRIGSBY, ERIC (OWNER)

Same official

Other billing entities under GRIGSBY, ERIC

Full network →

Provider	Location	Paid
Napa Biomedical Services, INC.	Napa, CA	$516.54

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.